Regen BioPharma, Inc.
RGBP · OTC
9/30/2025 | 9/30/2024 | 9/30/2023 | 9/30/2022 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | 0.00 | 0.00 | -0.10 | -0.06 |
| FCF Yield | -120.80% | -164.20% | -2.72% | -3.97% |
| EV / EBITDA | -3.28 | -2.96 | 2.25 | 5.52 |
| Quality | ||||
| ROIC | 7.65% | 9.52% | 15.80% | 5.03% |
| Gross Margin | 28.89% | 100.00% | 100.00% | 78.77% |
| Cash Conversion Ratio | 0.30 | 0.80 | -0.15 | -0.25 |
| Growth | ||||
| Revenue 3-Year CAGR | -18.82% | 0.15% | 11.38% | 28.89% |
| Free Cash Flow Growth | 44.66% | -298.54% | 71.34% | 46.33% |
| Safety | ||||
| Net Debt / EBITDA | -2.34 | -1.95 | 0.20 | 0.41 |
| Interest Coverage | 2.14 | -1.69 | -2.22 | -1.33 |
| Efficiency | ||||
| Inventory Turnover | 0.00 | 0.00 | 0.00 | 0.00 |
| Cash Conversion Cycle | 153.29 | 6.14 | 0.00 | 394.07 |